MORE►
clinical trial
Composite photo; source: CNW Group/Perimeter Medical Imaging AI Inc./DI Studio]
In a ‘First,’ Perimeter’s Claire AI‑Enabled Imaging Device for Breast Cancer Surgery Gains FDA Approval
by Sandra Engelland | Mar 4, 2026
Designated by the FDA as a Breakthrough Device, Claire is designed to enhance surgeons' ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for re-operations.
by David Seeley |
Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
MORE►
by Lance Murray |
May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
MORE►
by David Kirkpatrick |
Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE►
[Illustration: Vitanovski via iStock]
Fort Worth Biopharma Actuate Therapeutics Raises $21.7M in Series B Funding
by Lance Murray | May 20, 2019
The company said it will use the funding to expand its ongoing Phase 1 / 2 clinical trial and fund development programs.
MORE►
